Cardiovascular Prevention for Persons With HIV
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Infectious Disease, HIV / AIDS, HIV / AIDS |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 11/24/2017 |
| Start Date: | September 2009 |
| End Date: | May 2011 |
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study
This study is funded by the American Heart Association. The goal of this research is to
prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces
risk for heart disease in persons who are at increased risk (such as the case with HIV
infection).
Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT
need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants
will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure
medication (or a placebo), and will be seen at 3 study visits over 4 months.
prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces
risk for heart disease in persons who are at increased risk (such as the case with HIV
infection).
Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT
need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants
will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure
medication (or a placebo), and will be seen at 3 study visits over 4 months.
Inclusion Criteria:
- HIV Infection with viral load 'undetectable' while taking antiretroviral therapy
- Age ≥40
- Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral
therapy
Exclusion Criteria:
- Known cardiovascular disease or Framingham risk score (FRS) ≥20%
- Blood pressure ≥140/90
- LDL cholesterol ≥160 (with FRS <10%), or ≥130 (with FRS 10-20%)
- Currently taking, or has a medication contraindication to take, a 'statin', an ACE
inhibitor, or an angiotensin receptor blocker medication
- Cirrhosis or plasma ALT/AST levels >2x upper limit of normal
- Chronic kidney disease and a creatinine >2.0mg/dL
- Triglycerides >500mg/dL
We found this trial at
1
site
Click here to add this to my saved trials
